Aeris Therapeutics claims that the AeriSeal System provides a safer non-surgical alternative to lung volume reduction surgery, for treating patients with advanced emphysema.

The CE Mark approval enables Aeris Therapeutics to commercialise the system in Europe and other selected markets.

Aeris Therapeutics president and CEO David Dove said that the attainment of the CE Mark represents the achievement of another significant milestone in Aeris’ mission to improve the lives of patients with advanced lung diseases.

“The timing of this approval coincides with the presentation by investigators of positive clinical outcomes from our EU clinical trials at the 2010 Annual Congress of the European Respiratory Society in Barcelona this week. It allows us to promptly address immediate demand for new therapies for emphysema in the EU, a potential $7bn market opportunity,” Dove said.